AzTrials
AzTrials

Urinary Tract InfectionsCOLIGENURINCT07905638

Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)

An observational study of Urinary Tract Infections, run by Centre Hospitalier Universitaire de la Guadeloupe.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The aim is to identify genomic determinants (genes or gene clusters) associated with the severity of community-acquired E. coli urinary tract infections in Guadeloupe through a comparative approach integrating clinical, microbiological, and genomic data (GWAS approach). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Urinary Tract Infections
What is being tested?
Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
How many people
210 participants
Where
No sites listed yet
Study dates
Oct 2026to Oct 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults (≥ 18 years) born and living in Guadeloupe with a community-acquired urinary tract infection due to E. coli, managed at the CHU de la Guadeloupe between 1 March 2026 and 28 February 2027, for whom the E. coli isolate was stored (70 patients in each of 3 severity groups).

Who may be able to join

  • Age ≥ 18 years
  • Born and living in Guadeloupe
  • Community-acquired urinary tract infection managed in one of the following units between 1 March 2026 and 28 February 2027: adult emergency department, gynecological emergency department, infectious diseases, adult intensive care, urology, nephrology, endocrinology, or post-emergency unit
  • Positive urine culture (cytobacteriological examination of urine) for E. coli ≥ 10^3 CFU/mL
  • E. coli isolate stored
  • Patient (or relative/trusted person if the patient is unable to give agreement) who has not expressed opposition to participation in the study after being informed

Who cannot join

  • Nosocomial or healthcare-associated urinary tract infection
  • Polymicrobial culture
  • Asymptomatic bacteriuria not meeting the diagnostic threshold of ≥ 10^5 CFU/mL
  • Acute cystitis or febrile urinary tract infection not meeting the diagnostic threshold of ≥ 10^3 CFU/mL of E. coli
  • Patient under a legal protection measure (guardianship or curatorship)
  • Refusal of participation by the patient (or by the relative/trusted person if the patient is unable to give agreement)
  • Deceased patient who expressed, during his/her lifetime, opposition to the use of his/her health data for scientific purposes

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

The aim is to identify genomic determinants (genes or gene clusters) associated with the severity of community-acquired E. coli urinary tract infections in Guadeloupe through a comparative approach integrating clinical, microbiological, and genomic data (GWAS approach).

Read the detailed description

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, with nearly 150 million cases each year. They affect individuals across all age groups and represent a substantial burden in terms of public health and economic costs. While most cases begin as mild cystitis, UTIs can progress to severe forms such as pyelonephritis or bacteremia, particularly in the presence of predisposing factors such as urinary stasis, catheterization, or biofilm formation.

The predominant etiological agent is Escherichia coli, especially its uropathogenic strains (UPEC). These strains differ from commensal intestinal E. coli by their extensive arsenal of virulence factors enabling colonization and persistence within the urinary tract. A central mechanism is adhesion to urothelial cells, mediated notably by P fimbriae and PapG adhesin variants, whose distribution is associated with tissue tropism (papGII in pyelonephritis, papGIII in cystitis). UPEC also evade host immunity through the formation of intracellular bacterial communities and the production of 180 toxins such as hemolysin HlyA and cytotoxic necrotizing factor 1 (CNF1), which promote invasion and bacterial dissemination.

A major concern is the emergence of highly virulent and resistant clones. The Sequence Type (ST) 131 lineage exemplifies this convergence, combining virulence factors, biofilm formation, and multidrug resistance, notably through the production of CTX-M-type extended-spectrum beta-lactamases carried on plasmids with high dissemination potential. These characteristics make ST131 a key driver of complicated UTIs and therapeutic failures, posing a critical global public health challenge.

In the French Caribbean, and particularly in Guadeloupe, data linking the genomic profiles of UPEC strains to the clinical severity of infections remain scarce. Identifying genomic signatures predictive of disease severity would enable better patient stratification at the time of diagnosis and facilitate early adaptation of management strategies (targeted antibiotic therapy, hospitalization, or closer monitoring). With the development of high-throughput sequencing, bioinformatics, and artificial intelligence tools, personalized, preventive, and more efficient medicine is becoming increasingly achievable. Furthermore, recent studies have revealed that certain environmental strains share important genetic similarities with human pathogenic clones, suggesting possible inter-reservoir circulation. These findings underscore the importance of an integrated One Health approach, as promoted by the World Health Organization (WHO), which emphasizes the interconnectedness of human, animal, and environmental health. In an insular territory such as Guadeloupe, characterized by high population density, strong anthropogenic pressures, and fragile ecosystems, this approach is particularly relevant to understanding local transmission dynamics and anticipating the emergence of multidrug-resistant and/or highly virulent strains.

Being tested
Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
Keywords
Urinary tract infections, bacteremia, Escherichia coli, antibiotic resistance genes
Medical subject headings
Urinary Tract Infections, Bacteremia, Escherichia coli Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)Genetic

    Illumina sequencing of the E. coli isolate stored from the index urine culture, followed by bioinformatic analysis: assembly (SPAdes), annotation (Prokka), virulence and resistance genes and mobile genetic elements (VFDB, ResFinder), MLST/cgMLST typing, core-genome SNP phylogeny and pan-GWAS. Performed on strains collected during routine care; no additional procedure for patients.

Study groups in NCT07905638
Study groupRoleWhat they receive
Uncomplicated urinary tract infectionAdults with community-acquired E. coli urinary tract infection classified as uncomplicated: asymptomatic bacteriuria or acute cystitis
Receives: Genetic: Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
Febrile urinary tract infection without sepsisAdults with community-acquired E. coli febrile urinary tract infection without sepsis: simple acute pyelonephritis, pyelonephritis at risk of complications, or febrile UTI in men
Receives: Genetic: Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
Febrile urinary tract infection with sepsis and/or septic shockAdults with community-acquired E. coli febrile urinary tract infection with sepsis and/or septic shock (n = 70). For this group, the retrospective collection of stored isolates may be used, in addition to prospective inclusions, provided that the eligibility criteria defined in the protocol are met. This option aims to secure the feasibility of recruitment for these severe forms, whose frequency remains limited.
Receives: Genetic: Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Differential frequency of virulence genes or gene clusters in E. coli isolates, compared according to the severity level of community-acquired urinary tract infection

    pan-genome-wide association study

    Measured: At the end of the 12-month inclusion period

Secondary outcomes (3)
  1. Frequency and diversity of virulence and antibiotic resistance genes according to UTI severity (association between combined virulence/resistance profiles and severity levels)

    Genes identified from whole-genome sequences using VFDB and ResFinder.

    Measured: At the end of the 12-month inclusion period (genomic analysis of all stored isolates, performed after sequencing)]

  2. Clonal characteristics of the uropathogenic E. coli isolates and their distribution according to severity of the cases.

    sequence types by MLST, phylogroups)

    Measured: : At the end of the 12-month inclusion period (genomic analysis of all stored isolates, performed after sequencing)

  3. Genetic proximity between clinical and environmental E. coli isolates from Guadeloupe

    by MLST/cgMLST typing and core-genome SNP phylogeny

    Measured: At the end of the 12-month inclusion period (genomic analysis of all stored isolates, performed after sequencing)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionOct 2029 (estimated)
  4. Study completionOct 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
210 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07905638
Sponsor's protocol ID
CHUG_RIPH3_2026/03
Acronym
COLIGENURI
Status last verified
Sep 2026
First submitted
22 Oct 2026
Last updated
29 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Urinary Tract Infections, run by Centre Hospitalier Universitaire de la Guadeloupe.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sébastien BREUREC, Professor (+590 590 89 15 45, sebastien.breurec@chu-guadeloupe.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Differential frequency of virulence genes or gene clusters in E. coli isolates, compared according to the severity level of community-acquired urinary tract infection (time frame: At the end of the 12-month inclusion period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in